Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies by HARRIS, William S. et al.
ARTICLE
Blood n-3 fatty acid levels and total and cause-
specific mortality from 17 prospective studies
William S. Harris1,2✉, Nathan L. Tintle 2,3, Fumiaki Imamura 4, Frank Qian5,6, Andres V. Ardisson Korat6,
Matti Marklund7,8, Luc Djoussé6, Julie K. Bassett9, Pierre-Hugues Carmichael10, Yun-Yu Chen11,
Yoichiro Hirakawa12, Leanne K. Küpers13, Federica Laguzzi14, Maria Lankinen15, Rachel A. Murphy16,
Cécilia Samieri17, Mackenzie K. Senn18, Peilin Shi19, Jyrki K. Virtanen 15, Ingeborg A. Brouwer20,
Kuo-Liong Chien21,22, Gudny Eiriksdottir23, Nita G. Forouhi 4, Johanna M. Geleijnse 13, Graham G. Giles 24,
Vilmundur Gudnason 23,25, Catherine Helmer17, Allison Hodge 24, Rebecca Jackson26, Kay-Tee Khaw4,
Markku Laakso 27, Heidi Lai19,28, Danielle Laurin10,29, Karin Leander14, Joan Lindsay30, Renata Micha19,
Jaako Mursu15, Toshiharu Ninomiya31, Wendy Post9, Bruce M. Psaty32, Ulf Risérus33, Jennifer G. Robinson34,35,
Aladdin H. Shadyab36, Linda Snetselaar35, Aleix Sala-Vila2,37, Yangbo Sun35,38, Lyn M. Steffen39,
Michael Y. Tsai40, Nicholas J. Wareham 4, Alexis C. Wood18, Jason H. Y. Wu7, Frank Hu5,6, Qi Sun 5,6,
David S. Siscovick41, Rozenn N. Lemaitre 32, Dariush Mozaffarian 19 & The Fatty Acids and Outcomes
Research Consortium (FORCE)*
The health effects of omega-3 fatty acids have been controversial. Here we report the results
of a de novo pooled analysis conducted with data from 17 prospective cohort studies
examining the associations between blood omega-3 fatty acid levels and risk for all-cause
mortality. Over a median of 16 years of follow-up, 15,720 deaths occurred among 42,466
individuals. We found that, after multivariable adjustment for relevant risk factors, risk for
death from all causes was significantly lower (by 15–18%, at least p < 0.003) in the highest vs
the lowest quintile for circulating long chain (20–22 carbon) omega-3 fatty acids (eicosa-
pentaenoic, docosapentaenoic, and docosahexaenoic acids). Similar relationships were seen
for death from cardiovascular disease, cancer and other causes. No associations were seen
with the 18-carbon omega-3, alpha-linolenic acid. These findings suggest that higher circu-
lating levels of marine n-3 PUFA are associated with a lower risk of premature death.
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The n-3 polyunsaturated fatty acid (PUFA) family has beenthe subject of intense investigation ever since their inverseassociations with risk for acute myocardial infarction were
reported in Greenland Eskimos in the 1970s1,2. The PUFAs in
this family include the 18-carbon, plant-derived alpha-linolenic
acid (ALA,) as well as the 20–22-carbon, long-chain (LC, mostly
seafood-derived) eicosapentaenoic (EPA), docosapentaenoic
(DPA), and docosahexaenoic (DHA) acids.
The efficacy of the LC n-3 PUFAs in reducing risk for cardi-
ovascular disease (CVD) remains controversial as findings from
different randomized controlled trials (RCTs) have been con-
flicting. Nevertheless, a 2019 meta-analysis of RCTs reported
significant reductions in risk for myocardial infarction, coronary
heart disease (CHD) events and mortality, and CVD mortality in
patients randomized to supplemental LC n-3 PUFAs3. Another
meta-analysis of observational studies found that higher levels of
circulating LC n-3 PUFA levels were significantly associated with
a lower risk for CHD death4. However, no meta-analysis has yet
examined the relationship between LC n-3 PUFAs blood levels
and risk for all-cause mortality. Indeed, the only meta-analyses to
report a beneficial association with all-cause mortality were based
on the self-reported intake of fish5,6. Fish contain many nutrients
besides just LC n-3 PUFAs, self-reported food intake is memory
dependent, food databases can be out of date, and fish meals often
replace less healthful choices. As a result, studies that link LC n-3
PUFAs and health outcomes based on self-reported fish intake
have potential limitations. A more reliable and objective measure
of LC n-3 PUFA consumption is their level in the blood7 which is
primarily determined by the consumption of preformed LC n-3
PUFAs (although synthesis from dietary ALA can make a small
contribution8). Hence a clearer picture of the biological rela-
tionship between LC n-3 PUFAs and disease outcomes may be
obtained from biomarker-based investigations.
Some studies have reported inverse relations between n-3
PUFA biomarkers and total mortality9–11, while others have
not12,13. In the Cardiovascular Health Study, higher LC n-3
PUFA levels also were associated with overall “healthier aging”
(i.e., surviving past age 65 free of chronic diseases and
maintaining good functional status)14. However, reports from
studies of individual cohorts can be limited by insufficient power
and inconsistent adjustment for potential confounding factors. In
addition, publication bias can distort summary conclusions. To
address these challenges, the present study pooled de novo
individual-level analyses across 17 prospective cohort studies in
the Fatty Acid and Outcome Research Consortium (FORCE)15 to
explore the associations of circulating levels of n-3 PUFAs (both
plant- and seafood-derived) and all-cause mortality. Secondarily,
we examined the associations with mortality from CVD, cancer,
and all other causes.
Here, we show significant inverse associations for all mortality
endpoints with the LC n-3 PUFA levels. Hence, chronically
higher tissue levels of these FAs operating through a variety of
potential mechanisms may slow the aging process.
Results
Population. The pooled analyses included circulating n-3 PUFA
measurements on 42,466 individuals, 15,720 (37%) of whom died
during follow-up (Table 1). At baseline, the average age was 65
years (range of mean ages across cohorts was 50–81 years), 55%
were women (range of 0–100% across cohorts) and the median
follow-up time was 16 years (range of 5–32 years across cohorts).
Whites constituted 87% of the sample. Circulating levels of the n-
3 PUFAs (and of the n-6 PUFAs linoleic and arachidonic acids,
which were included as covariates) are shown in Supplementary
Fig. 1 and in Supplementary Table 2. Supplementary Table 3
shows the number of cause-specific deaths from participating
cohorts. Overall, approximately 30% of the deaths were attributed
to CVD, 30% to cancer, and the remaining 39% to all other
causes.
Total mortality. Comparing the medians of the first and fifth
quintiles (i.e., approximately the 90th and the 10th percentiles),
higher EPA, DPA, DHA, and EPA+DHA levels were associated
with between 9% and 13% lower risk of all-cause mortality
(Table 2). (The fatty acid levels associated with these percentiles
Table 1 Baseline characteristicsa of 17 prospective cohort studies included in the meta-analysis: Fatty Acids and Outcomes
Research Consortium.











60YO Sweden 1997–1999 19.5 3659 (756) 60.0 52.0 26.7 Plasma CE
AGES-R Iceland 2002–2006 9.4 1697 (962) 76.9 55.2 27.2 Plasma PL
CCCC Taiwan 1990–1991 18.9 1834 (993) 60.6 44.0 23.3 Plasma
CHS United States 1992–1993 13.3 2256 (1872) 74.8 38.8 26.6 Plasma PL
CSHA Canada 1991–1992 5.1 424 (19) 80.9 61.0 25.8 RBC PL
EPIC-Norfolk United Kingdom 1993–1997 17.4 6613 (3347) 62.9 50.3 26.6 Plasma PL
FHS United States 2008 7.3 2123 (292) 65.4 56.6 28.3 RBC PL
Hisayama Japan 2002 10.2 3293 (469) 61.5 57.2 23.0 Plasma
HPFS United States 1994 20.5 1477 (878) 64.6 0.0 25.9 RBC PL
KIHD Finland 1998–2001 17.9 1125 (310) 61.8 48.3 27.4 Plasma
MCCS Australia 1990–1994 23.2 3796 (902) 54.5 54.8 26.9 Plasma PL
MESA United States 2000–2002 14.0 1844 (111) 69.8 5 28.4 Plasma PL
MetSIM Finland 2006–2010 9.6 1354 (58) 55.0 0.0 26.5 Plasma PL
NHS United States 1989–1990 24.1 1487 (853) 60.4 100 25.5 RBC PL
3C France 1999–2001 15.0 1421 (787) 74.6 63.1 26.3 Plasma
ULSAM Sweden 1970–1973 32.1 1878 (1771) 49.7 0.0 25.0 Plasma CE
WHIMS United States 1996 13.0 6185 (1340) 70.1 100 28.4 RBC PL
aBaseline characteristics at the time of fatty acid biomarker measurement.
Abbreviations of cohorts: 60YO, Stockholm cohort of 60-year olds, AGES-R Age, Genes, Environment Susceptibility Study (Reykjavik), CCCC Chin-Shan Community Cardiovascular Cohort Study, CHS
Cardiovascular Health Study, CSHA Canadian Study of Health and Aging, EPIC-Norfolk European Prospective Investigation into Cancer, Norfolk UK, FHS Framingham Heart Study, HPFS Health
Professionals Follow-up Study, KIHD Kuopio Ischemic Heart Disease Risk Factor Study, MCCS Melbourne Collaborative Cohort Study, MESA Multi-Ethnic Study of Atherosclerosis, MetSIM Metabolic
Syndrome in Men Study, NHS Nurses’ Health Study, 3C Three-City Study, ULSAM Uppsala Longitudinal Study of Adult Men, WHIMS Women’s Health Initiative Memory Study. CE cholesteryl esters, PL
phospholipids, RBC red blood cells.
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for each cohort and sample type are shown in Supplementary
Table 4). The HR for total mortality for EPA+DHA was 0.87
(95% CI: 0.83–0.90) (Fig. 1). In contrast, ALA was not sig-
nificantly associated with all-cause mortality [HR 0.99
(0.96–1.02)]. In an across quintiles analysis, significant trends
were observed for EPA, DPA, DHA, and EPA+DHA (all < 0.01);
and comparing the top to the bottom quintile, each was asso-
ciated with 15–18% lower risk of death (Table 3). There was little
evidence for nonlinearity in these inverse associations for all each
LC n-3 PUFAs except for EPA (p= 0.002 for the nonlinearity;
Fig. 2). The relationship of EPA with mortality was most pro-
nounced at lower levels and then appeared to plateau at higher
levels. ALA was generally unassociated with total mortality,
except for a borderline association in the top quintile [HR 0.94
(0.89–0.99); P-trend= 0.13], and there was no evidence for
nonlinearity (Supplementary Fig. 2).
Cause-specific mortality. Comparing the 90th to the 10th per-
centile, each of the LCn-3 PUFAs was significantly associated
Table 2 Associations of circulating n-3 PUFA biomarkers with risk of total and cause-specific mortality in 17 cohorts: Fatty Acids
and Outcomes Research Consortium.
Fatty acid All-cause mortality
HR (95% CI)
(17 cohorts; 15,720 deaths)
CVD mortality
HR (95% CI)
(15 cohorts; 4571 deaths)
Cancer mortality
HR (95% CI)
(15 cohorts; 4284 deaths)
Other mortality
HR (95% CI)
(14 cohorts; 6022 deaths)
ALA 0.99 (0.96–1.02) 1.01 (0.95–1.07) 1.02 (0.96–1.08) 0.99 (0.95–1.04)
EPA 0.91 (0.88–0.94) 0.88 (0.83–0.94) 0.91 (0.85–0.96) 0.92 (0.87–0.97)
DPA 0.87 (0.84–0.91) 0.91 (0.84–0.99) 0.87 (0.81–0.95) 0.88 (0.82–0.94)
DHA 0.89 (0.85–0.92) 0.86 (0.80–0.92) 0.93 (0.86–1.00) 0.90 (0.84–0.95)
EPA+DHA 0.87 (0.83–0.90) 0.85 (0.79–0.91) 0.89 (0.83–0.96) 0.88 (0.82–0.93)
Hazard ratios (HRs) and 95% CIs expressed per cohort-specific inter-quintiles range comparing the midpoint of the top and bottom quintiles (see Supplementary Table 4 for cohort-specific n-3 PUFA
values). All HRs are adjusted for age, sex, race, field center, body-mass index, education, occupation, marital status, smoking, physical activity, alcohol intake, prevalent diabetes, hypertension, and
dyslipidemia, self-reported general health, and the sum of circulating n-6 PUFA (linoleic plus arachidonic acids). See Supplementary Table 4 for the 10th and 90th percentile values from each cohort for
each PUFA of interest and the average PUFA values per lipid pool. Abbreviations: ALA alpha-linolenic acid, CI confidence interval, CVD cardiovascular disease, DHA docosahexaenoic acid, DPA
docosapentaenoic acid, EPA eicosapentaenoic acid, HR hazard ratio.
Fig. 1 Adjusted hazard ratios (HR, 95% CI) for total mortality for circulating eicosapentaenoic (EPA) plus docosahexaenoic acid (DHA) in the 17
contributing studies of the Fatty Acids and Outcomes Research Consortium. Study-specific estimates for HRs (dark squares) are shown per interquartile
range (comparing the midpoint of the top to the bottom quintiles) their sizes indicate study weights (column 3). The horizontal line through each HR is
95% CI. Compartments included erythrocyte phospholipids, plasma phospholipids, cholesteryl esters, and total plasma. All HRs are adjusted for age, sex,
race, field center, body-mass index, education, occupation, marital status, smoking, physical activity, alcohol intake, prevalent diabetes, hypertension, and
dyslipidemia, self-reported general health, and the sum of circulating n-6 PUFA (linoleic plus arachidonic acids). See Table 1 footnote for abbreviations of
cohorts.
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with a lower risk for death from CVD, cancer, and all other causes
combined [except for DHA and cancer mortality, HR 0.93
(0.86–1.00)] (Table 2). ALA was not significantly associated with
any cause-specific mortality. Evaluating the trend across quintiles,
EPA, DHA, and EPA+DHA were inversely associated with
CVD death, EPA and DPA were inversely associated with cancer
death, and each of the LC n-3 PUFAs was inversely associated
with other death. Comparing the top to the bottom quintile, EPA,
DPA, DHA, and EPA+DHA were each significantly, inversely
associated with CVD, cancer, and other mortality (Table 3).
Heterogeneity and sensitivity analyses. Inter-cohort hetero-
geneity was at least moderate (I2 > 50%) in the pooled analyses of
all-cause mortality for all n-3 PUFAs except ALA (I2= 26%) and
EPA (I2= 41%), while heterogeneity for cause-specific mortality
ranged from little to moderate (0–56%) (Supplementary Table 5).
There was little evidence of differential associations with mor-
tality by PUFA lipid compartment after accounting for multiple
testing (5 PUFAs × 4 outcomes; Bonferroni correction 0.05/20=
0.0025, Supplementary Table 6). Likewise, associations of n-3
PUFAs with total mortality were similar across strata based on
age, sex, race, and fish oil use (Supplementary Table 7), with no
significant differences after accounting for multiple testing
(5 PUFAs × 4 strata results; Bonferroni correction 0.05/20=
0.0025). Overall findings did not change with the removal of
participants taking fish oil (Supplementary Table 7) or in the
drop-one-cohort analyses.
Discussion
In this meta-analysis utilizing a harmonized analytical strategy
with individual-level data from 17 cohorts, we examined the
associations between circulating levels of the n-3 PUFAs and
mortality. We found that, after controlling for other major risk
factors, LC n-3 PUFAs (but not ALA) were associated with about
a 15–18% lower risk of total mortality comparing the top to the
bottom quintiles. These relationships were generally linear for
DPA, DHA, and EPA+DHA, but not for EPA. For this PUFA
there was a steeper risk reduction across the lower blood levels
but little additional difference in risk at higher blood levels.
Inverse correlations were also generally observed between LC n-3
PUFA levels and CVD, cancer, and other causes of death.
This pooled analysis including over 40,000 participants and
over 15,000 deaths greatly expands upon the findings of prior
individual cohort studies that examined associations of circulat-
ing levels of n-3 PUFAs and all-cause mortality9–13,16–24. Rela-
tively few studies have evaluated self-reported dietary fish (or
estimated n-3 PUFA) intake in relation to total mortality, but
those that have typically support our observations here5,22,25,26.
Interestingly, reported use of fish oil supplements was linked to a
Table 3 Meta-analysis of circulating n-3 PUFA biomarkers with mortality types by cohort-specific quintiles (hazard ratios and
95% CIsa): Fatty Acids and Outcomes Research Consortium.








ALA Q1 1 1 1 1
Q2 0.95 (0.87–1.04) 0.95 (0.87–1.04) 0.98 (0.89–1.08) 0.94 (0.87–1.01)
Q3 0.94 (0.89–0.99) 1.00 (0.91–1.10) 0.96 (0.87–1.05) 0.93 (0.86–1.00)
Q4 0.95 (0.90–1.01) 0.99 (0.91–1.09) 0.99 (0.90–1.09) 0.95 (0.88–1.03)
Q5 0.94 (0.89–0.99) 0.98 (0.89–1.08) 0.88 (0.80–0.98) 0.93 (0.86–1.01)
P for Trendb 0.13 0.96 0.14 0.32
EPA Q1 1 1 1 1
Q2 0.92 (0.87–0.97) 0.98 (0.90–1.07) 0.90 (0.82–0.99) 0.91 (0.84–0.98)
Q3 0.88 (0.83–0.92) 0.98 (0.90–1.07) 0.86 (0.78–0.95) 0.86 (0.79–0.93)
Q4 0.85 (0.81–0.90) 0.89 (0.81–0.98) 0.87 (0.78–0.96) 0.83 (0.77–0.90)
Q5 0.82 (0.78–0.87) 0.85 (0.77–0.94) 0.82 (0.74–0.91) 0.78 (0.72–0.85)
P for Trend <0.0001 0.006 0.008 <0.0001
DPA Q1 1 1 1 1
Q2 0.95 (0.90–1.01) 0.96 (0.87–1.07) 0.96 (0.86–1.07) 0.94 (0.86–1.02)
Q3 0.92 (0.87–0.98) 0.99 (0.89–1.09) 0.98 (0.88–1.10) 0.91 (0.84–0.99)
Q4 0.90 (0.85–0.96) 0.98 (0.88–1.09) 0.92 (0.82–1.03) 0.88 (0.80–0.96)
Q5 0.84 (0.79–0.90) 0.87 (0.78–0.98) 0.79 (0.70–0.90) 0.85 (0.78–0.93)
P for Trend 0.0001 0.16 0.008 0.007
DHA Q1 1 1 1 1
Q2 0.95 (0.90–1.00) 0.96 (0.88–1.05) 0.91 (0.83–1.00) 0.96 (0.89–1.04)
Q3 0.92 (0.88–0.97) 0.87 (0.80–0.95) 0.88 (0.80–0.97) 0.97 (0.89–1.05)
Q4 0.97 (0.94–1.01) 0.92 (0.84–1.01) 0.91 (0.83–1.00) 0.90 (0.83–0.97)
Q5 0.85 (0.81–0.90) 0.79 (0.72–0.88) 0.86 (0.78–0.95) 0.87 (0.80–0.94)
P for Trend 0.01 0.002 0.06 0.008
EPA+DHA Q1 1 1 1 1
Q2 0.94 (0.89,0.99) 0.96 (0.88,1.04) 0.93 (0.85–1.03) 0.93 (0.86–1.00)
Q3 0.92 (0.88,0.97) 0.91 (0.83,1.00) 0.90 (0.82–0.99) 0.94 (0.87–1.02)
Q4 0.89 (0.84,0.93) 0.86 (0.79,0.95) 0.92 (0.83–1.02) 0.89 (0.82–0.96)
Q5 0.84 (0.79,0.89) 0.80 (0.73,0.88) 0.87 (0.78–0.96) 0.82 (0.75–0.89)
P for Trend <0.0001 0.0004 0.06 0.0008
aExpressed per cohort-specific quintiles (see Supplementary Table 4 for cohort-specific n-3 PUFA values). All hazard ratios are adjusted for age, sex, race, field center, body-mass index, education,
occupation, marital status, smoking, physical activity, alcohol intake, prevalent diabetes, hypertension, and dyslipidemia, self-reported general health, and the sum of circulating n-6 PUFA (linoleic plus
arachidonic acids).
bP-for trend is computed by using a fixed-effects, inverse weighted meta-regression analysis, i.e., the hazard estimates were regressed against study quintiles, which we assigned a value of 1, 2, 3, 4, or 5.
Abbreviations: ALA alpha-linolenic acid, CI confidence interval, CVD cardiovascular disease, DHA docosahexaenoic acid, DPA docosapentaenoic acid, EPA eicosapentaenoic acid.
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lower risk for death from any cause in a study from the UK
including over 427,000 individuals27.
Associations with total and cause-specific mortality were not
significant for the plant-derived n-3 PUFA ALA. Prior biomarker-
based meta-analyses reported inverse associations of ALA with
CHD death, but relationships with total or CVD mortality were
not examined4,28. Whether our finding of no association ALA on
CVD mortality was because ALA has no role to play in fatal
strokes (included in the CVD mortality metric) or because of
differences in the cohorts included in these prior meta-analyses vs.
the present one is not clear. Circulating ALA levels are less
dependable markers of intake compared with the LC n-3 PUFAs
because this fatty acid is rapidly β-oxidized and, to a small extent,
converted into the LC n-3 PUFAs8. Nevertheless, the borderline
and inconsistent relations of ALA on mortality risk deserve
further study.
Higher circulating levels of LC n-3 PUFAs may beneficially
affect diverse cellular systems that together could contribute to a
reduced risk for death. The mechanisms behind the ostensibly
beneficial effect of LC n-3 PUFAs on human biology are multiple
and have been summarized in several recent reviews papers29–32.
Among them are hypotriglyceridemic, antihypertensive, and
antiplatelet effects; as well as positive effects on adipocyte biology,
endothelial function, and autonomic balance. All of these appear
to be mediated by effects on membrane physiochemistry, gene
expression, and the production of a myriad of bioactive oxylipins.
Persistently lower levels of inflammatory biomarkers also char-
acterize those with higher circulating LC n-3 PUFA levels33. These
fatty acids have been reported to inhibit the mammalian (or
mechanistic) target of rapamycin (mTOR) in animal studies
showing benefits in cancer34, metabolic syndrome35, spinal cord
injury36, and depression37. mTOR inhibition extends lifespan in
many species38 and acts as an energy sensor to coordinate gene
expression, ribosome biogenesis, and mitochondrial metabolism39.
In the Heart and Soul Study, where whole blood EPA+DHA
levels were inversely associated with all-cause mortality24, higher
levels were also linked with a slower rate of telomere shortening
over a 5-year period40. As higher rates of telomere attrition have
been associated with shorter overall lifespan41,42, this finding may
be secondary to the more distal biochemical mechanisms noted
above. Regardless of their specific actions, higher cellular levels of
the LC n-3 PUFAs appear to slow the aging process.
Our findings of lower risk of CVD death with high vs. low
blood levels of EPA+DHA are generally consistent with meta-
analyses of self-reported fish intake25 and of biomarker levels4, as
well as randomized controlled clinical trials of n-3 PUFA
supplementation3,43 (although the most recent trial44 has not yet
been included in meta-analyses). Compared with CVD, evidence
for a link between n-3 PUFAs and cancer mortality risk is sparse,
with no significant relationship for self-reported estimates of fish
or n-3 PUFA consumption25,45. Meta-analyses of RCTs with n-3
PUFA supplements also have not observed effects on cancer,
although short-term durations of such trials (generally up to 5
years) would likely preclude any ability to detect an effect on
cancer46,47. The difference between these findings and what we
observed may arise from the use of biomarker levels instead of
self-reported fish intake. Biomarkers are potentially truer reflec-
tions of long-term exposure, making it easier to detect subtle
relationships. In addition, circulating LC n-3 PUFA levels reflect
endogenous metabolism, especially for DPA which is not corre-
lated with estimated dietary DPA intake48 but may have impor-
tant biologic effects49. Finally, since neurodegenerative diseases
are a major non-CVD, non-cancer cause of death, a report that
higher fish intake was associated with reduced mortality from this
cause6 is consistent with our observations here.
Although circulating marine n-3 PUFA levels have not been
measured in all of the major intervention trials, the doses of EPA
+DHA used in most trials (<1 g/day) may not have resulted in
marked differences in levels between treated and control
patients50. For example, in the Vitamin D and Omega-3 Trial
(VITAL) trial, treatment with 840 mg of EPA+DHA per day
increased plasma phospholipid EPA+DHA levels from 2.7 to
4.1%, a 55% increase. This relatively small difference in LC n-3
PUFA levels between the placebo and active treatment groups
could be one of the potential reasons for the failure of some RCTs
to detect an effect of n-3 PUFAs on CV outcomes50,51. Future
RCTs may be more effective if they focus on people with low
baseline levels of LC n-3 PUFAs52 and provide doses of EPA and
DHA that produce higher blood levels. An intake of about 250 mg
of EPA+DHA per day as recommended in the Dietary Guide-
lines for Americans53 may raise circulating levels into the ranges
observed here for some but not all adults7.
Although a significant effect on the primary (composite)
endpoint in the VITAL trial47 was not achieved, our findings
comport well with some of its secondary findings. In this study,
the provision of 840 mg of EPA+DHA/day significantly reduced
risk for major CV events and myocardial infarction in those
participants with lower (vs. higher) intakes of fish (blood levels in
these groups were not reported). There was a significant inter-
action of fish intake on total mortality as well; the HR (95% CI) in
the low intake group was 0.87 (0.73–1.04) and in the high intake
group, 1.19 (0.99–1.44, p for interaction 0.017). This secondary
observation in VITAL implies that individuals with lower baseline
LC n-3 PUFA levels are more likely to benefit from increased
levels than those with higher baseline levels. Two recent RCTs
examining the effects of high dose (~3–4 g/day) of LC n-3 PUFAs
were performed in overweight patients with high blood trigly-
ceride levels and at high risk for CVD events, all on background
Fig. 2 Associations of circulating long-chain n-3 PUFA levels with all-
cause mortality: nonlinear dose-response meta-analysis in the Fatty
Acids and Outcomes Research Consortium. Hazard ratios and cohort-
specific quantiles are presented in the vertical and horizontal axis,
respectively. The best estimates and their confidence intervals are
presented as black lines and gray-shaded areas, respectively. The 10th
percentile was selected as a reference level and the x-axis depicts 5th to
95th percentiles. Potential nonlinearity was identified for EPA (p= 0.0004)
but not for the others (p > 0.05). All HRs are adjusted for age, sex, race,
field center, body-mass index, education, occupation, marital status,
smoking, physical activity, alcohol intake, prevalent diabetes, hypertension,
and dyslipidemia, self-reported general health, and the sum of circulating n-
6 PUFA (linoleic plus arachidonic acids).
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statin therapy. After 5 years of treatment, Bhatt et al.54 reported
beneficial effects of EPA ethyl esters on CV events, whereas
Nicholls et al.44 found no effect on the primary outcome using an
EPA+DHA product in which the fatty acids were non-esterified.
Another 2-year trial in elderly post-MI patients from Norway
given 1.8 g of EPA+DHA found no benefit on CV outcomes55.
None of these trials is directly relevant to our findings here owing
to the nature of the high-risk patient populations, the number of
concurrent background medications, the short duration of
treatment, and the initiation of treatment late in life.
Strengths of the current analysis include the use of objective n-
3 PUFA biomarkers (instead of estimated intakes from dietary
questionnaires) which increases the accuracy of exposure
assessment and allows for separate analysis of different individual
n-3 PUFAs. The use of prespecified, harmonized, de novo
individual-level analyses across multiple cohorts substantially
increase generalizability, reduces confounding through consistent
adjustment for covariates, and limits the potential for publication
bias. The pooling of 17 studies including over 15,000 deaths also
increased the statistical power to evaluate mortality subtypes as
well as potential heterogeneity across subgroups.
Potential limitations deserve attention. Because our outcome
was not rare, the hazard ratios (HRs) reported here (instanta-
neous relative risk) may be modestly different than the cumula-
tive relative risk. Most individuals were White, potentially
lowering generalizability to other races/ethnicities, although our
analysis still included nearly 6000 non-Whites in whom findings
for EPA+DHA were generally similar to those for Whites
(Supplementary Table 7). Despite extensive efforts to harmonize
study-specific methods, moderate heterogeneity remained
between studies that may be due to unmeasured background
population characteristics, differences in laboratory assessment of
PUFAs and of outcomes, chance, or any combination of these.
PUFAs and covariates were measured once at baseline, and
changes over time could lead to misclassification, which could
bias the results in uncertain directions. On the other hand, rea-
sonable reproducibility has been reported for n-3 PUFA bio-
marker concentrations over time56. Because analytical methods,
even within the same lipid fraction, were not standardized, and n-
3 PUFA levels were measured in multiple fractions, we assessed
cohort-specific n-3 PUFA percentiles rather than absolute per-
centages of total fatty acids in each fraction. Since FA levels were
reported as a percent of total FAs in each lipid compartment,
levels of one FA could affect levels of another. Indeed, in the
plasma or RBC PL and CE pools, higher levels of the LC n-3
PUFAs (which were the focus of this study) are linked with lower
levels of the n-6 PUFAs but not of saturated or mono-unsaturated
FAs57,58. Since we adjusted for differences in linoleic and ara-
chidonic levels in our analyses, this concern was accounted for.
Each lipid pool used in this study reflects LC n-3 PUFA intake
during relatively different and overlapping time periods generally
from months to weeks following this hierarchy: RBC ≥ Plasma
PL ≈ Plasma CE ≥ total plasma59,60. In addition, we cannot rule
out the potential for residual confounding. That is, higher LC n-3
PUFA levels may simply be markers of a “healthy lifestyle,” and
the fatty acids themselves may not be playing any physiological
role in postponing death but would be biomarkers of a suite of
other healthy behaviors (dietary/exercise/non-smoking, etc.), or
endogenous metabolic processes, that might, in a multiplicity of
ways, manifest in greater longevity. Although we adjusted for
many major risk factors (age, income, marital status, smoking,
hyperlipidemia, hypertension, etc.), residual confounding by
other factors is always possible. However, the magnitude of the
observed effect of the meta-analysis of circulating LC n-3 PUFAs
and total mortality reported herein is consistent with the known
associations with CHD mortality and sudden cardiac death61,62.
Finally, as the attribution of cause of death is never as unam-
biguous as death itself, some uncertainty must attend to the
cause-specific analyses reported here. In summary, in a global
pooled analysis of prospective studies, LC n-3 PUFA levels were
inversely associated with risk for death from all causes and from
CVD, cancer, and other causes.
Methods
Study design and population: FORCE Consortium. The study was conducted
within FORCE15, a consortium of observational studies with fatty acid biomarker
data and ascertained chronic disease events4. For the current project, 48 pro-
spective studies in the consortium as of December 2018 were invited to participate.
Of these, seven did not have relevant data (e.g., no mortality outcomes or no
circulating PUFA levels at baseline), two included only participants with prevalent
CVD, 13 indicated a lack of funding/analyst time and 9 did not respond after at
least 5 separate invitations to participate over a 9-month period. The study sample
comprised data from 17 studies across 10 countries with available data on circu-
lating PUFA levels at baseline and mortality during follow-up. The details of each
individual study are presented in Supplementary Table 1. All participating studies
followed a prespecified standardized analysis protocol with harmonized inclusions
and exclusions, exposures, outcomes, covariates, and analytical methods including
assessment of missing covariate data and statistical models. In each study, new
analyses of individual data were performed according to the protocol, and study-
specific results were collected using a standardized electronic form. Information
regarding registration for any of the cohorts included herein (that required it prior
to study initiation) is shown in Supplementary Table 1.
Individual cohorts conducted their studies in accordance with the criteria set by
the Declaration of Helsinki, and informed consent was obtained from all
participants. The review boards or ethics committees from each cohort were as
follows: 60YO (Ethical Committee at the Karolinska Institut); AGES-R (Icelandic
Heart Association and the Intramural Research Program of the National Institute
on Aging); CCCC (National Taiwan University Research Ethics Committee); CHS
(Tufts University Research Ethics Committee); CSHA (Laval University and the
Research Center of the Centre Hospitalier Affilie Universitaire); EPIC-Norfolk
(Norfolk Research Ethics Committee); FHS (Boston University Institutional
Review Board); Hisayama (Kyushu University Certified Institutional Review
Board); HPFS (Human Subjects Review Committee of the Harvard School of
Public Health); KIHD (Research Ethics Committee of the University of Kuopio);
MCCS (Cancer Council Victoria Human Research Ethics Committee); MESA
(University of Washington Human Subjects Division); MetSIM (Ethics Committee
of the University of Eastern Finland and Kuopio University Hospital); NHS
(Human Research Committee at the Brigham and Women’s Hospital); 3C
(Consultative Committee for the Protection of Persons participating in Biomedical
Research at Kremlin-Bicêtre University Hospital); ULSAM (Swedish Ethical
Review Authority); and WHIMS (Fred Hutchinson Cancer Research Center
Institutional Review Board).
Study participants in the included cohorts (a) were >18 years old, (b) had no
major medical diagnoses (prior myocardial infarction, prior stroke, severe active
cancer, severe renal disease, severe liver, or lung disease), (c) were not taking
supplemental fish oil, and (d) did not die within a year of baseline. The one
exception to (c) was the inclusion of the Age, Genes, Environment Susceptibility
Study (Reykjavik) (AGES-R) from Iceland63 in which 68% of participants reported
taking cod liver oil. This factor was adjusted for in the AGES-R analysis, and
participants in AGES-R taking cod liver oil were also excluded in a sensitivity
analysis.
Fatty acid measurements. Participating studies measured PUFAs in at least one
blood compartment, including plasma phospholipids, cholesterol esters, ery-
throcytes, and whole plasma. All PUFA levels were reported as a percent of total
fatty acids. Detailed information regarding PUFA measurement methods for each
study is in Supplementary Table 1.
Outcome assessment. The primary endpoint of this study was total mortality
(death from any cause). Additional endpoints of interest were deaths from CVD,
cancer, and all other causes. Detailed information on the definitions of the out-
comes used in each cohort is included in Supplementary Table 1.
Covariates. Prespecified covariates included age (continuous), sex (men/women),
race (binary: White/non-White), field center (categories), body-mass index (con-
tinuous), education (less than high school graduate, high school graduate, at least
some college or vocational school), occupation (if available), marital status (mar-
ried, never married, widowed, divorced), smoking (current, former, never), phy-
sical activity (kcal/week, METS/week, or hours/day), alcohol intake (drinks or
servings/day, g/day or ml/day), prevalent diabetes mellitus (treated or physician-
diagnosed), prevalent hypertension (treated or physician-diagnosed), prevalent
dyslipidemia (treated or physician-diagnosed), self-reported general health (if
available) and circulating n-6 PUFA levels (i.e., the sum of linoleic and arachidonic
acids). If individual cohorts could not categorize these covariates exactly according
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to these definitions, then study-specific categories were used as surrogates. Missing
variables were handled as detailed in the Online Supplementary Materials.
Statistical analysis and pooling. Study-specific analyses were harmonized across
cohorts. They were carried out using Cox proportional hazards models using
robust variance estimates to calculate the multivariable-adjusted HRs in each study,
with follow-up from the date of biomarker measurement to date of death, loss to
follow-up, or end of follow-up. Associations and relevant statistical interactions
were also assessed in prespecified strata within each cohort by age (<60 vs. ≥60),
sex, and race (White vs. non-White). To allow comparison and pooling of results
from different biomarker compartments, n-3 PUFA levels were standardized to the
study-specific inter-quintiles range defined as the range between the medians of the
top and bottom quintile categories (i.e., about the 90th and 10th percentiles). In
addition, each cohort computed HRs across study-specific quintiles, with the lowest
quintile as the reference. Pooling by quintiles instead of absolute fatty acid values
were necessary because values differ by lipid compartment. Nevertheless, such an
approach was reasonable given the observed correlations among different lipid
compartments. For example, the Pearson correlations between EPA+DHA levels
(i.e., percent of total fatty acids) in RBC and CE, PL, and whole plasma are 0.83,
0.88, and 0.93, respectively (unpublished data from Harris lab based on 49 samples
analyzed in all four compartments).
Meta-analysis. Cohort-specific HRs were pooled by inverse-variance weighted
meta-analysis. Heterogeneity was assessed by the I2 statistic and Q-test. Hetero-
geneity was further explored by meta-analyzing prespecified subgroups. Sensitivity
analyses included (1) the removal of those subjects from AGES-R who reported fish
oil use, and (2) re-analysis after the removal of each cohort one at a time. The
potential for a nonlinear association of each n-3 PUFA with all-cause mortality was
examined with a multivariable meta-analysis with a restricted cubic spline
technique64 as detailed in Online Supplementary Materials. Stata 15.1 (Stata Corp.,
College Station, TX) was used for spline fitting and testing. All the other meta-
analyses were conducted using the metafor package65 in R version 366. A two-
tailedP value of <0.05 was considered to be statistically significant unless otherwise
specified, e.g., in the exploratory analyses by subgroups and lipid compartments.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Policies for data-sharing vary between the cohorts depending on their original human
subjects' approvals and existing procedures. For approved data-sharing requests, types of
data that may be shared can include demographics, exposures, covariates, and outcomes.
Please contact each individual principal investigator for cohort-specific data requests (See
Supplementary Table 1).
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